<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04610619</url>
  </required_header>
  <id_info>
    <org_study_id>NL72351.091.20</org_study_id>
    <nct_id>NCT04610619</nct_id>
  </id_info>
  <brief_title>Multisystem Features of Malignant Hyperthermia or Rhabdomyolysis Related to RYR1 Variants</brief_title>
  <official_title>The Neuromuscular and Multisystem Features of RYR1-related Malignant Hyperthermia and Rhabdomyolysis - a Study Protocol</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Radboud University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Canisius-Wilhelmina Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Radboud University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Rationale: Malignant hyperthermia and rhabdomyolysis are phenotypes that have long been&#xD;
      considered to occur only in response to external stimuli (trigger anaesthesia and physical&#xD;
      exhaustion) show several features of a continuous disease manifestation. Previous studies&#xD;
      showed prolonged bleeding time after injury, selective immunological advantages, axial muscle&#xD;
      weakness and several social difficulties. A detailed study of the neuromuscular and&#xD;
      multisystem features of patients with RYR1-related malignant hyperthermia or rhabdomyolysis&#xD;
      is needed to provide clarification about the continuous and multisystem disease&#xD;
      manifestations in these patients.&#xD;
&#xD;
      Objective:&#xD;
&#xD;
      Primary Objective: There are three primary objectives in this study.&#xD;
&#xD;
        1. To investigate the neuromuscular involvement of RYR1 related MH and rhabdomyolysis.&#xD;
&#xD;
        2. To investigate the immunological changes in subjects with RYR1 related MH and&#xD;
           rhabdomyolysis.&#xD;
&#xD;
        3. To identify multisystem features of RYR1 related MH and rhabdomyolysis.&#xD;
&#xD;
      There are no secondary objectives.&#xD;
&#xD;
      Study design: The design of the study will be a clinical, open, observational study. The&#xD;
      study consists of three parts; a clinical, imaging and immunological part.&#xD;
&#xD;
      Study population: Patients with a history of malignant hyperthermia susceptibility (MHS),&#xD;
      and/or a history of rhabdomyolysis related to a variant in RYR1.&#xD;
&#xD;
      Intervention (if applicable): Not applicable.&#xD;
&#xD;
      Main study parameters/endpoints: The study consists of three parts. Each part has it's own&#xD;
      main study parameters&#xD;
&#xD;
        1. Clinical part: the results of the questionnaire study compared to standardizes normal&#xD;
           values and the results of the comprehensive clinical assessment.&#xD;
&#xD;
        2. Imaging part: fatty infiltration and hypertrophy of proximal and axial muscles.&#xD;
&#xD;
        3. Immunological part: circulating and leukocyte released anti- and pro-inflammatory&#xD;
           cytokine levels compared to healthy age and sex matched controls.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 19, 2020</start_date>
  <completion_date type="Anticipated">January 2022</completion_date>
  <primary_completion_date type="Anticipated">January 2022</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <target_duration>1 Year</target_duration>
  <primary_outcome>
    <measure>To investigate the neuromuscular involvement of RYR1 related MH and rhabdomyolysis</measure>
    <time_frame>Directly after inclusion, a muscle MRI's and ultra sounds will be made of all subjects.</time_frame>
    <description>All subjects will have a total body muscle MRI and muscle ultra sound once</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To investigate the multisystem features of RYR1 related MH and rhabdomyolysis</measure>
    <time_frame>Directly after inclusion, subjects will fulfil a questionnaire study.</time_frame>
    <description>All subject will fulfil a questionnaire study, it will focus on pain, activity and psychological aspects.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To investigate the multisystem features of RYR1 related MH and rhabdomyolysis</measure>
    <time_frame>Six months after inclusion, subjects will fulfil a questionnaire study.</time_frame>
    <description>All subject will fulfil a questionnaire study, it will focus on pain, activity and psychological aspects.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To investigate the multisystem features of RYR1 related MH and rhabdomyolysis</measure>
    <time_frame>Twelve months after inclusion, subjects will fulfil a questionnaire study.</time_frame>
    <description>All subject will fulfil a questionnaire study, it will focus on pain, activity and psychological aspects.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To investigate the immunological changes in subjects with RYR1 related MH and rhabdomyolysis.</measure>
    <time_frame>Directly after inclusion blood samples will be taken for immunological studies.</time_frame>
    <description>Peripheral mononuclear blood cells will be isolated and in vitro challenged using pathogens and stimulatia. The results of this part of the study will be compared to healthy controls.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Malignant Hyperthermia</condition>
  <condition>Rhabdomyolysis</condition>
  <condition>RYR1 Variant</condition>
  <arm_group>
    <arm_group_label>RYR1 related malignant hyperthermia/rhabdomyolysis</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Immunological challenge</intervention_name>
    <description>In vitro immunological study of subjects with RYR1 related MH/rhabdomyolysis. Studying of circulating cytokines and cytokines production after in vitro stimulation</description>
    <arm_group_label>RYR1 related malignant hyperthermia/rhabdomyolysis</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with RYR1 related malignant hyperthermia/rhabdomyolysis&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  A history of malignant hyperthermia susceptibility (MHS), confirmed by diagnostic RYR1&#xD;
             variant or IVCT, related to a RYR1 variant and/or a history of rhabdomyolysis related&#xD;
             to a variant in RYR1&#xD;
&#xD;
          -  Minimum age 18 years old.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients diagnosed with a neuromuscular disease resulting in muscle weakness (apart&#xD;
             from RYR1 related rhabdomyolysis and malignant hyperthermia).&#xD;
&#xD;
          -  Patients with symptoms of angina pectoris.&#xD;
&#xD;
          -  Patients with contra-indications for MRI-scan are excluded. Contra-indications for&#xD;
             MRI-scan include metallic implants (vascular clips, foreign bodies like metallic&#xD;
             splinters in the eye, coronary and peripheral artery stents, prosthetic heart valves,&#xD;
             pacemakers and ICD's, cochlear implants, breast tissue expanders and some other&#xD;
             electronic implants or devices and known claustrophobia.&#xD;
&#xD;
          -  Current malignancy&#xD;
&#xD;
          -  Pregnancy or lactating&#xD;
&#xD;
          -  Other health issues whereby patients are not able to fulfil the study protocol&#xD;
&#xD;
          -  No written informed consent by the patient&#xD;
&#xD;
        Exclusion criteria for immunological part of the study:&#xD;
&#xD;
          -  Diabetes mellitus&#xD;
&#xD;
          -  Patients currently using medicine affecting the immune system.&#xD;
&#xD;
          -  Patients with a compromised immunity (e.g. HIV)â€¢ Patients with a history of&#xD;
             auto-immune disease (e.g. SLE, psoriasis, IBD)&#xD;
&#xD;
          -  Use of statins the past year&#xD;
&#xD;
          -  Use of systemic corticosteroids during more than two weeks in the past 5 years&#xD;
&#xD;
          -  Previous treatment with chemotherapy and/or radiation therapy&#xD;
&#xD;
          -  Age &gt; 65 years old.&#xD;
&#xD;
        Exclusion criteria for healthy controls&#xD;
&#xD;
          -  History of malignant hyperthermia&#xD;
&#xD;
          -  Variant in RYR1&#xD;
&#xD;
          -  A RYR1 related myopathy&#xD;
&#xD;
          -  History of heat stroke&#xD;
&#xD;
          -  History of rhabdomyolysis&#xD;
&#xD;
          -  Family history of malignant hyperthermia or a RYR1 variant&#xD;
&#xD;
          -  Family history of inexplicable perioperative dead&#xD;
&#xD;
          -  Family history of a RYR1 related myopathy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>RUniversity</name>
      <address>
        <city>Nijmegen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luuk van den Bersselaar, M.D. MSc</last_name>
      <phone>+31 24 361 1111</phone>
      <email>luuk.vandenbersselaar@radboudumc.nl</email>
    </contact>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 17, 2020</study_first_submitted>
  <study_first_submitted_qc>October 29, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 30, 2020</study_first_posted>
  <last_update_submitted>July 26, 2021</last_update_submitted>
  <last_update_submitted_qc>July 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rhabdomyolysis</mesh_term>
    <mesh_term>Hyperthermia</mesh_term>
    <mesh_term>Fever</mesh_term>
    <mesh_term>Malignant Hyperthermia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The study protocol will be shared with other researchers</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

